Aerie Pharma (AERI) – Major News
-
Alcon (ALC) Acquires Aerie Pharmaceuticals (AERI) for $15.25/sh or $770M
-
Aerie Pharma (AERI) Tops Q2 EPS by 24c
-
Aerie Pharma (AERI) Reports In-Line Q1 EPS
-
Aerie Pharma (AERI) Tops Q4 EPS by 176c
-
Aerie Pharma (AERI) Misses Q3 EPS by 10c
-
Aerie Pharma (AERI) Misses Q2 EPS by 3c
-
Aerie Pharma (AERI) Misses Q1 EPS by 23c
-
Aerie Pharma (AERI) Misses Q4 EPS by 27c
-
Aerie Pharma (AERI) Misses Q2 EPS by 25c
-
Aerie Pharma (AERI) Misses Q1 EPS by 7c
-
Aerie Pharma (AERI) Misses Q4 EPS by 44c
-
Aerie Pharma (AERI) Misses Q3 EPS by 29c; Lowers Revenue Guidance
-
Aerie Pharma (AERI) Tops Q2 EPS by 6c
-
Aerie Pharma (AERI) Misses Q1 EPS by 14c
-
Aerie Pharma (AERI) Misses Q4 EPS by 5c
-
Aerie Pharma (AERI) Misses Q3 EPS by 35c
-
Aerie Pharma (AERI) Reports Q2 Loss of $1.40/Share
-
Aerie Pharma (AERI) Misses Q1 EPS by 18c
-
Aerie Pharma (AERI) Misses Q4 EPS by 11c
-
Aerie Pharma (AERI) Confirms FDA Approval of Rhopressa 0.02% for Lowering of Elevated IOP in Patients with Open-Angle Glaucoma or Ocular Hypertension
-
Aerie Pharma (AERI) Misses Q3 EPS by 7c
-
Aerie Pharma (AERI) Misses Q2 EPS by 1c
-
Aerie Pharma (AERI) Roclatan 0.02%/0.005% Phase 3 Trial Achieves Primary Efficacy Endpoint
-
Aerie Pharma (AERI) Tops Q1 EPS by 5c
-
Aerie Pharma (AERI) Misses Q4 EPS by 5c
-
Aerie Pharma (AERI) RhopressaTM Manufacturing Line Will Not Be Ready for Pre-Approval Inspection Until End of Feb 17
-
Aerie Pharma (AERI) Reports In-Line Q3 EPS
-
Aerie Pharma (AERI) Tops Q2 EPS by 2c
-
Aerie Pharma (AERI) Misses Q1 EPS by 8c
-
Aerie Pharma (AERI) Tops Q4 EPS by 8c
-
Aerie Pharma (AERI) Tops Q3 EPS by 10c
-
Aerie Pharma (AERI) Announces Rhopressa Phase 3 Met Primary Efficacy Endpoint
-
Aerie Pharma (AERI) Tops Q2 EPS by 11c
-
Aerie Pharma (AERI) Gets Positive Feedback from FDA on Rhopressa, to Modify Endpoint Range in Rocket 2 Trial
-
Aerie Pharmaceuticals (AERI) RhopressaTM Phase 3 Trial Fails to Meet Primary Endpoint
-
Aerie Pharma (AERI) Misses Q4 EPS by 12c
-
Aerie Pharmaceut (AERI) Posts Q4 Loss of 62c/Share
-
Aerie Pharmaceut (AERI) Reports Q3 Loss of $10.81
-
Aerie Pharmaceuticals (AERI) IPO Opens Modestly Higher
Back to AERI Stock Lookup